OTCMKTS:HLTRF HLS Therapeutics (HLTRF) Stock Price, News & Analysis $3.80 +0.05 (+1.33%) As of 08/18/2025 02:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About HLS Therapeutics Stock (OTCMKTS:HLTRF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HLS Therapeutics alerts:Sign Up Key Stats Today's Range$3.70▼$3.8050-Day Range$3.57▼$3.8052-Week Range$2.24▼$3.80Volume900 shsAverage Volume1,513 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada. Read More Receive HLTRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HLTRF Stock News HeadlinesHLS Therapeutics Secures New Credit Agreement for Financial FlexibilityAugust 20 at 9:11 AM | tipranks.comHLS Therapeutics Inc.: Strategic Positioning and Growth Potential Justify Buy RatingMay 11, 2025 | tipranks.comI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning about a dangerous flaw in America’s financial system for 15 years, he believed Trump might fix it. Instead, he says the problem has only grown worse. In his new emergency broadcast, Breaking Point, Porter reveals why this flaw may now be irreversible—and how it could gut retirement accounts, trigger mass wealth destruction, and blindside hard-working investors.August 22 at 2:00 AM | Porter & Company (Ad)HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicinesMay 9, 2025 | msn.comHLS Therapeutics Inc (HLTRF) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...May 9, 2025 | finance.yahoo.comHLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in CanadaMay 8, 2025 | finance.yahoo.comHLS Therapeutics Partners with Esperion to Bring Cardiovascular Treatments to CanadaMay 8, 2025 | tipranks.comHLS Therapeutics to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceApril 28, 2025 | finance.yahoo.comSee More Headlines HLTRF Stock Analysis - Frequently Asked Questions How have HLTRF shares performed this year? HLS Therapeutics' stock was trading at $2.69 at the start of the year. Since then, HLTRF stock has increased by 41.3% and is now trading at $3.80. How do I buy shares of HLS Therapeutics? Shares of HLTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:HLTRF CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees91Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (OTCMKTS:HLTRF) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HLS Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.